Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate

David Hosking, Kenneth Lyles, Jacques P Brown, William D Fraser, Paul Miller, Manuel Diaz Curiel, Jean-Pierre Devogelaer, Michael Hooper, Guoqin Su, Ken Zelenakas, Judy Pak, Taiwo Fashola, Youssef Saidi, Erik Fink Eriksen, Ian R Reid

Research output: Contribution to journalArticlepeer-review

135 Citations (Scopus)


A single 5-mg infusion of zoledronic acid restores biochemical markers of bone turnover into the reference range in the majority of patients with Paget's disease and maintains biochemical remission for at least 2 years. This effect is largely independent of pretreatment disease activity and prior bisphosphonate therapy.
Original languageEnglish
Pages (from-to)142-148
Number of pages7
JournalJournal of Bone and Mineral Research
Issue number1
Publication statusPublished - Jan 2007


  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Alkaline Phosphatase
  • Bone Density Conservation Agents
  • Bone and Bones
  • Diphosphonates
  • Etidronic Acid
  • Follow-Up Studies
  • Humans
  • Imidazoles
  • Infusions, Intravenous
  • Osteitis Deformans

Cite this